Shanghai Hippocrates Health Technology Co., Ltd. and Beijing Dishi Consulting Co., Ltd., which have  been deeply engaged for many years in the fields of life sciences and data sciences, announced today that they have officially signed a strategic cooperation agreement. The agreement is aimed at jointly promoting the efficient processing of clinical research data and the development of digital technologies in the life sciences field by integrating the professional technologies and industry experience of both parties.

I. Background of Cooperation

As a high-tech enterprise, Shanghai Hippocrates Health Technology Co., Ltd. focuses on IT informatization construction in the pharmaceutical industry and boasts rich experience in cloud computing, CA certification, and artificial intelligence (AI) technology R&D. Beijing Dishi Consulting Co., Ltd., on the other hand, possesses profound professional knowledge and practical experience in data sciences and clinical research, particularly excelling in the implementation of clinical data standards and automated/intelligent data processing, analysis, and visualization.

II. Cooperation Content

This strategic cooperation will be carried out around the following core areas:

1. Data Science and Clinical Research Management: The two parties will jointly develop and optimize clinical research business processes, data management processes, and related tool development to improve the efficiency and quality of clinical research.
2. CDISC Standard Implementation: Leveraging Beijing Dishi Consulting Co., Ltd.’s expertise in CDISC standard implementation and combining it with Shanghai Singdi Health Technology Co., Ltd.’s technology platform, the two parties will jointly promote the popularization and application of CDISC standards in China.
3. Training and Promotion: Through organizing activities related to CDISC, data sciences, and automation in China, the two parties will jointly drive the development of industry standards and the cultivation of professional talents.
4. Business Cooperation: Each party will give play to its own advantages – Shanghai Singdi Health Technology Co., Ltd. will be responsible for business promotion for both parties, while Beijing Dishi Consulting Co., Ltd. will provide pre-sales support (covering data sciences, process optimization, and compliance).

III. Significance of Cooperation

This strategic cooperation will not only enhance the market competitiveness of the two companies in their respective fields but also provide more comprehensive and efficient solutions for pharmaceutical enterprises. By integrating the resource and technological advantages of both parties, the two companies aim to promote the unification of industry standards, improve the quality and efficiency of clinical research, and ultimately bring safer and more effective treatment options to patients.

IV . Future Outlook

Both Beijing Dishi Consulting Co., Ltd. and Shanghai Hippocrates Health Technology Co., Ltd. are full of expectations for this cooperation. They believe that through joint efforts, they can contribute to the development of the life sciences field and lay a solid foundation for the long-term development of both parties.

V. About Beijing Dishi Consulting Co., Ltd.

Founded in 2015, Beijing Dishi Consulting Co., Ltd. derives its Chinese name "Dishi" from the transliteration of its English name "Data Science Express". The company has accumulated rich experience in data sciences and clinical research, particularly standing out in protocol design, sample size calculation, randomization and blinding implementation, statistical design/analysis/programming implementation, data management/governance, and data science process optimization/automation/intelligentization. In addition, Beijing Dishi Consulting Co., Ltd. has significant advantages in CDISC standard implementation, including the application of CDASH, SDTM, and ADaM standards, as well as multi-region/country data submission and translation and validation services for data submission packages. The company is committed to improving the efficiency and quality of clinical research data processing and analysis through automated tools, and actively participates in the localization (sinicization) and promotion of CDISC standards to drive the development of the industry.

VI. About Hippocrates

Named after Hippocrates, the father of ancient Greek medicine, Hippocrates has over 20 years of industry experience. The company started with GMP compliance consulting and has grown into a leading provider of pharmaceutical digital solutions in China. We have participated in the drafting of national GxP digital standards and possess strong capabilities in both consulting and independent R&D. Our products comply with GxP standards and meet the regulatory requirements of global authorities such as the NMPA, FDA, EMA, and WHO. Our self-developed QMS, DMS, and TMS suites rank among the top tier in China. We also offer VDR, eSIGN, PVS, EBR, WMS, CGT, and eMAH solutions, along with one-stop services covering compliance control, data governance, and CSV validation, supporting both group-level and global deployment. Our clients include leading domestic pharmaceutical companies, benchmark biotech enterprises, and multinational pharmaceutical companies. To date, we have helped hundreds of companies achieve zero-defect audits, empowering pharmaceutical enterprises in digital transformation, cost reduction, efficiency improvement, and global growth.